查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1995456

切片检查设备市场：按产品类型、引导技术、应用和最终用户划分－2026-2032年全球市场预测

Biopsy Devices Market by Product Type, Guidance Technique, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年切片检查设备市场价值为 81.3 亿美元，预计到 2026 年将成长至 88.3 亿美元，复合年增长率为 9.43%，到 2032 年将达到 153 亿美元。

主要市场统计数据
基准年 2025 81.3亿美元
预计年份：2026年 88.3亿美元
预测年份 2032 153亿美元
复合年增长率 (%) 9.43%

对切片检查设备市场进行简明基本概述，涵盖临床因素、技术进步、监管影响以及主要企业的采购重点。

切片检查デバイスは、肿疡学、肾臓学、肝臓学、呼吸器内科における诊断プロセスの中核をなしており、その进化は临床ワークフロー、デバイスの导入、および调达优先顺位に直接的な影响を与えています。现代の促进要因としては、技术革新、手技の标准化、そして患者の快适性と诊断的収率を优先する低侵袭技术への注目の高まりが挙げられます。同时に、规制当局の监视や支払者侧の政策が、デバイスの设计、临床エビデンスの创出、および価値の证明に影响を与えており、これらが相まって、あらゆる医疗现场における导入速度を决定づけています。

详细概述了技术融合、自动化以及临床工作流程的演变，这些工作流程正在重塑医疗环境中切片检查设备的使用和检验。

切片检查デバイスの状况は、画像诊断、自动化、データ駆动型诊断における进歩の融合によって牵引される変革的な変化を遂げており、これらの动向は切片检查の実施方法やケアパスへの统合の在り方を再构筑しています。画像诱导による标的选定技术は成熟し、より小さな病変のより正确なサンプリングを可能にし、再处置の必要性を低减しています。同时に、洗练された针配置システムや真空补助抽出といったサンプリング机构の自动化により、检体の完全性が向上し、操作者によるばらつきが减少しており、これが下流の分子およびゲノム解析を支えています。

对 2025 年关税趋势将如何重塑切片检查设备利益相关者的供应链韧性、筹资策略和製造本地化进行全面分析。

2025年に発表または実施された関税政策の変更がもたらす累积的な影响は、切片检查机器分野における调达、サプライチェーン计画、および竞合上のポジショニングに新たな复雑さを加えています。関税は、国境を越えた製造や组装に依存する部品や完成品のコスト构造を変化させる可能性があります。特に、复数の管辖区域から调达される精密金属、ポリマー、电子サブシステムを组み込んだシステムにおいてその影响は顕着です。これに対応するため、メーカー各社は、追加の输入関税によるリスクを軽减し、価格竞争力を维持するために、サプライヤーの拠点配置、物流戦略、契约条件を见直しています。

整合细分洞察，揭示产品类型、临床应用和医疗保健环境如何相互交织，并定义绩效要求、购买行为和开发重点。

洞察に富んだセグメンテーション分析により、临床ニーズと设计上の选択が交差する点、および商业性的机会が最も集中している领域が明确になります。製品タイプ别に见ると、市场は粗针切片システム、内视镜ソリューション、细针吸引ツール、および真空补助プラットフォームに及びます。粗针切片システムには、展开速度と操作者の制御性を両立させた自动および半自动のバリエーションが含まれており、これらの选択は、高スループットな组织标的や复雑な组织标的における适性を左右します。内视镜デバイスは、柔软型と硬性型の构成によって区别され、これらは解剖学的部位へのアクセス可能性や、既存の内视镜システムとの互换性を决定します。细针吸引法には、细胞诊や分子検査のための检体采取の适切性を优先する吸引駆动型および手动技术が含まれ、一方、真空补助プラットフォームは、高い处理能力を提供する主机型ソリューションから、携帯性と照护现场での使用を重视するハンドヘルドデバイスまで多岐にわたります。

区域趋势和采用路径决定了美洲、欧洲、中东和非洲以及亚太地区的采购偏好、监管限制和临床重点。

地域ごとの动向は、导入パターン、偿还枠组み、および规制経路を形作り、南北アメリカ、欧州、中东・アフリカ、アジア太平洋の各地域において、それぞれ异なる机会を生み出しています。南北アメリカでは、成熟した肿疡学ケアネットワークと画像诱导下介入の広范な导入が、高度なサンプリング技术への需要を支えています。一方、民间および公的保険者环境は、実证可能な価値と业务効率への注力を促しています。政策立案者や医疗システムは、入院期间を短缩し、外来での管理を可能にするイノベーションに対してますます前向きになっており、これにより、外来诊疗环境に対応した医疗设备が有利な立场にあります。

以永续性为重点，透过平台整合、临床检验、客户培训和产品演进实现差异化，进行策略竞争格局分析。

切片检查デバイス市场における竞合情势は、卓越したエンジニアリングと、确固たる临床的检验、そして包括的なサービス提供を组み合わせる能力によって、ますます决定づけられるようになっています。主要企业は、复数の解剖学的ターゲットに合わせてアップグレードや适応が可能なモジュラー型プラットフォームに投资しており、これにより製品のライフサイクルが延长され、医疗提供者の投资収益率（ROI）が向上します。画像诊断企业、病理检查室、デジタルヘルスベンダーとの戦略的提携により、检体采取と下流の分析を结びつけるエコシステムが构筑され、统合ケアチームに対する価値提案が强化されています。

为製造商和供应商提供可操作的策略建议，以增强临床证据、供应链韧性、客户采纳流程和互通性，从而实现永续成长。

业界の领导企业は、临床エビデンスの创出、サプライチェーンのレジリエンス、顾客中心の商业化、互通性という4つの戦略的重点分野を优先することで、洞察を実行可能な计画へと転换することができます。第一に、実临床における有効性や手技上の利点を実证する包括的な临床研究への投资は、保険偿还に関する议论を强化し、懐疑的な临床医グループにおける导入を后押しすることになります。こうした取り组みには、多施设共同の観察研究、縦断的アウトカムを収集するレジストリ、および下流の诊断的価値を実证するための病理检查室との连携を含めるべきです。

为了支持可靠的结论，我们采用了一种透明的混合方法调查方法，整合了主要临床发现、医疗设备技术审查、监管文献和情境分析。

本研究途径では、质的専门家インタビュー、デバイス性能评価、规制および临床文献の比较分析を组み合わせ、坚牢かつ説得力のあるエビデンス基盘を构筑します。主なインプットとして、インターベンショナルラジオロジスト、胸部・乳腺外科医、病理医、调达负责人との构造化された议论を行い、実临床における手技の选好、课题、导入の促进要因を把握しました。これらの观点は、デバイスアーキテクチャ、製造上の考虑事项、サービスモデルに関する技术的评価と照らし合わせることで、临床ニーズと技术的现実を整合させました。

简明扼要地总结了技术进步、临床检验的必要性以及供应链考虑因素，以确定切片检查设备相关人员的策略重点。

要するに、切片检查デバイスは、技术の进歩、変化する临床ワークフロー、そして外部からの経済的圧力が交错し、リスクと机会の両方を生み出す転换点に立っています。标的精度、自动化、プラットフォーム间の互通性におけるイノベーションが诊断プロセスを向上させている一方で、医疗提供者の期待や支払者による精査により、临床的および运用上の価値を示す明确なエビデンスの必要性が高まっています。收费系统の动向やサプライチェーンの対応により、现地化とレジリエンス（回復力）に向けた戦略的転换が加速しており、利害相关人员にとってはリスクを积极的に评価し、调达および製造戦略を调整することが不可欠となっています。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：切片检查设备市场：依产品类型划分

  • 芯针
    • 自动的
    • 半自动
  • 内视镜
    • 灵活的
    • 硬度
  • 细针穿刺
    • 吸
    • 手动的
  • 吸力型
    • 主机类型
    • 手持式

第九章：切片检查设备市场指南

  • 影像引导切片检查
  • 非影像引导切片检查

第十章：切片检查设备市场：依应用领域划分

  • 胸部
    • 诊断
    • 筛检
  • 肾
    • 剖腹手术
    • 经皮
  • 肝
    • 经皮
    • 经颈静脉
  • 肺
    • 经支气管
    • 经胸壁
  • 摄护腺
    • 会阴经
    • 经直肠

第十一章：切片检查设备市场：依最终用户划分

  • 门诊手术中心
  • 诊所
  • 诊断检查室
  • 医院

第十二章：切片检查设备市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：切片检查设备市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：切片检查设备市场：按国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国切片检查设备市场

第十六章：中国切片检查设备市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Angiotech Pharmaceuticals, Inc.
  • Argon Medical Devices, Inc.
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Cardinal Health, Inc.
  • CONMED Corporation
  • Cook Group Incorporated
  • Danaher Corporation
  • DTR Medical Ltd. by Innovia Medical
  • Fujifilm Holdings Corporation
  • Gallini Srl
  • Hologic, Inc.
  • INRAD, Inc.
  • Intact Medical Corporation
  • Integra LifeSciences Corporation
  • Leica Biosystems Nussloch GmbH
  • Medtronic PLC
  • Merit Medical Systems
  • Olympus Corporation
  • Precision Biopsy, LLC
  • Scion Medical Technologies, LLC
  • Stryker Corporation
  • TransMed7, LLC
  • TSK Laboratory Europe BV
Product Code: MRR-4103B31E073F

The Biopsy Devices Market was valued at USD 8.13 billion in 2025 and is projected to grow to USD 8.83 billion in 2026, with a CAGR of 9.43%, reaching USD 15.30 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.13 billion
Estimated Year [2026] USD 8.83 billion
Forecast Year [2032] USD 15.30 billion
CAGR (%) 9.43%

Concise foundational overview of biopsy device landscape capturing clinical drivers, technological advances, regulatory influences, and procurement priorities for leaders

Biopsy devices are central to diagnostic pathways across oncology, nephrology, hepatology, and pulmonary medicine, and their evolution directly shapes clinical workflows, device adoption, and procurement priorities. Contemporary drivers include a convergence of technological innovation, procedural standardization, and an increasing focus on minimally invasive techniques that prioritize patient comfort and diagnostic yield. In parallel, regulatory scrutiny and payer policies are influencing device design, clinical evidence generation, and value demonstration, which together determine adoption speed across care settings.

Clinicians are demanding devices that reduce procedure time while enhancing sample quality, particularly as molecular diagnostics and next-generation sequencing become routine components of clinical decision-making. As a result, manufacturers are directing development toward precision-guided systems, automation of sampling mechanisms, and platforms that integrate with digital pathology and data management tools. At the same time, providers are balancing capital investment with throughput needs, which elevates the importance of lifecycle costs, training requirements, and interoperability with existing imaging and endoscopy suites.

Moving forward, stakeholders must reconcile clinical imperatives with economic realities. Procurement teams and clinical leaders are increasingly looking for evidence of real-world effectiveness and operational benefits beyond controlled trials. Therefore, device developers and strategy teams should prioritize robust clinical validation, user-centered design, and clear value narratives that resonate with both proceduralists and hospital administrators. Taken together, these elements create a complex but actionable landscape for innovation and adoption in biopsy technologies.

Detailed synthesis of technological convergence, automation, and clinical workflow evolution that is reshaping biopsy device utilization and validation across care settings

The biopsy device landscape is undergoing transformative shifts driven by converging advances in imaging, automation, and data-driven diagnostics, and these trends are reshaping how biopsies are performed and integrated into care pathways. Image-guided targeting has matured, enabling more accurate sampling of smaller lesions and reducing the need for repeat procedures. Concurrently, automation in sampling mechanics, such as refined needle deployment systems and vacuum-assisted extraction, is improving sample integrity and reducing operator variability, which in turn supports downstream molecular and genomic analyses.

Additionally, there is a noticeable shift toward platform thinking, where devices are developed to interoperate with digital pathology workflows, electronic health record systems, and cloud-based data repositories. This facilitates longitudinal tracking of samples, integration of diagnostic metadata, and support for multidisciplinary care teams making complex treatment decisions. Another important dynamic is the movement of procedures from inpatient wards to ambulatory surgical centers and clinic-based settings, driven by demand for convenience, resource optimization, and procedural efficiency.

Regulatory pathways are adapting to these technological shifts, emphasizing evidence of clinical utility and post-market surveillance. As a result, manufacturers are investing earlier in clinical outcomes studies and in building data capture mechanisms that demonstrate improved diagnostic confidence, reduced complications, and enhanced patient throughput. Taken together, these transformative shifts create opportunities for innovation while raising the bar for clinical validation and commercial readiness.

Comprehensive analysis of how 2025 tariff developments are reshaping supply chain resilience, procurement strategies, and manufacturing localization for biopsy device stakeholders

The cumulative impact of tariff policy changes announced or implemented in 2025 introduces a layer of complexity for procurement, supply chain planning, and competitive positioning in the biopsy device arena. Tariffs can alter cost structures for components and finished devices that rely on cross-border manufacturing and assembly, particularly for systems incorporating precision metals, polymers, and electronic subsystems sourced from multiple jurisdictions. In response, manufacturers are reassessing supplier footprints, logistics strategies, and contractual terms to mitigate exposure to incremental import duties and to preserve pricing competitiveness.

Clinicians and hospital procurement teams should expect an emphasis on total cost of ownership analyses that account for potential tariff-driven price volatility. Some manufacturers may absorb tariff impacts temporarily to maintain market access, whereas others will recalibrate pricing or shift production to locations with more favorable trade terms. These adjustments can create short-term supply constraints or lead times as suppliers requalify new manufacturing sites or reroute logistics. In turn, providers may face delays in obtaining replacement parts or elective devices, which underscores the importance of inventory planning and of establishing reliable service agreements.

Beyond operational effects, tariffs can influence strategic decisions around localization, vertical integration, and partnerships. Organizations that proactively evaluate nearshoring, dual sourcing, or component standardization will better manage risk and cost predictability. Furthermore, transparent communication between manufacturers and customers about supply continuity plans, warranty implications, and service-level expectations becomes critical. In sum, tariff-induced perturbations in 2025 will not only affect pricing but also accelerate structural shifts across supply chains and commercial strategies.

Integrated segmentation insights revealing how product types, clinical applications, and care settings converge to define performance needs, purchasing behavior, and development priorities

Insightful segmentation analysis clarifies where clinical needs intersect with design choices and where commercial opportunities are most concentrated. By product type, the landscape spans core needle systems, endoscopic solutions, fine needle aspiration tools, and vacuum-assisted platforms. Core needle systems include both automatic and semi-automatic variants that balance deployment speed with operator control, and these choices influence suitability across high-throughput and complex tissue targets. Endoscopic devices are differentiated by flexible and rigid configurations, which determine accessibility to anatomical sites and compatibility with existing endoscopy suites. Fine needle aspiration encompasses aspiration-driven and manual techniques that prioritize sample adequacy for cytology and molecular assays, while vacuum-assisted platforms range from console-based solutions offering higher throughput to handheld devices that favor portability and point-of-care use.

When considering application, clinical priorities vary by organ system and by the procedural approach used. Breast applications include diagnostic procedures and screening-focused interventions, requiring devices that support high sample fidelity and patient comfort. Kidney procedures are performed via open or percutaneous approaches, each imposing distinct device ergonomics and needle performance needs. Liver sampling is primarily percutaneous or transjugular, and device selection must account for vascular access considerations and bleeding risk. Lung biopsies executed via transbronchial or transthoracic routes demand tools compatible with bronchoscopic guidance or percutaneous imaging, respectively. Prostate procedures employ transperineal and transrectal approaches, and the growing emphasis on infection control and sampling accuracy is affecting device preference and clinical protocols. From an end-user perspective, procedures occur across ambulatory surgical centers, clinics, diagnostic laboratories, and hospitals, and each setting imposes constraints around capital expenditure, staffing expertise, throughput expectations, and sterilization infrastructure.

Integrating these segmentation perspectives enables stakeholders to prioritize product development, training investments, and commercial strategies that are aligned with clinical workflows and institutional capabilities.

Regional dynamics and adoption pathways that define procurement preferences, regulatory constraints, and clinical priorities across the Americas, Europe Middle East & Africa, and Asia-Pacific geographies

Regional dynamics shape adoption patterns, reimbursement frameworks, and regulatory pathways, creating differentiated opportunities across the Americas, Europe, Middle East & Africa, and Asia-Pacific regions. In the Americas, mature oncology care networks and widespread adoption of image-guided interventions support demand for advanced sampling technologies, while private and public payer environments drive a focus on demonstrable value and operational efficiency. Policymakers and health systems are increasingly receptive to innovations that reduce hospital stays and enable outpatient management, which favors devices compatible with ambulatory settings.

In Europe, Middle East & Africa, regulatory harmonization efforts and diverse healthcare financing models create a nuanced landscape where clinical evidence, cost-effectiveness, and compliance are key determinants of uptake. Several markets in this region emphasize centralized procurement and tender-based purchasing, which elevates the importance of long-term service agreements and competitive total cost propositions. Meanwhile, in the Asia-Pacific region, rapid investments in diagnostic infrastructure, expanding access to specialist care, and growing capacity for complex laboratory testing are stimulating interest in devices that deliver high-quality samples for molecular analysis. Local manufacturing capabilities and regional supply chain strategies also influence device pricing and availability, and partnerships with local distributors or contract manufacturers remain a pragmatic route to market expansion.

Across all regions, differences in clinical guidelines, training availability, and institutional priorities require tailored market approaches that reflect local regulatory expectations, reimbursement nuances, and operational realities.

Strategic competitor landscape analysis highlighting differentiation through platform integration, clinical validation, customer training, and sustainability-driven product evolution

Competitive positioning within the biopsy device landscape is increasingly determined by the ability to pair engineering excellence with robust clinical validation and comprehensive service offerings. Leading firms are investing in modular platforms that can be upgraded or adapted for multiple anatomical targets, which extends product lifecycles and enhances return on investment for providers. Strategic collaborations with imaging companies, pathology labs, and digital health vendors are creating ecosystems that link sample acquisition to downstream analytics, thereby strengthening value propositions for integrated care teams.

Manufacturers differentiating through customer support and training programs are gaining market preference, since procedural success and device utilization are tightly linked to operator proficiency. Additionally, a growing emphasis on sustainability and device reusability is prompting companies to explore materials science innovations and sterilization protocols that reduce environmental impact without compromising patient safety. Competitive strategies also include geographic diversification, selective pricing models tailored to public and private payers, and the development of financing arrangements that lower barriers to adoption in capital-constrained settings.

Innovation pipelines reflect a balance between incremental improvements-such as ergonomics and needle coatings-and disruptive approaches that combine robotics, real-time imaging, and AI-assisted targeting. Organizations that can demonstrate improved procedural outcomes, reduced complication rates, and streamlined workflows are well positioned to secure long-term partnerships with high-volume providers and integrated health systems.

Actionable strategic recommendations for manufacturers and providers to fortify clinical evidence, supply chain resilience, customer adoption pathways, and interoperability for sustained growth

Industry leaders can translate insights into actionable plans by prioritizing four strategic thrusts: clinical evidence generation, supply chain resilience, customer-centric commercialization, and interoperability. First, investing in comprehensive clinical studies that document real-world effectiveness and procedural advantages will strengthen reimbursement discussions and support adoption among skeptical clinician groups. These efforts should include multicenter observational studies, registries that capture longitudinal outcomes, and collaborations with pathology labs to demonstrate downstream diagnostic value.

Second, strengthening supply chain resilience through diversification, nearshoring, and robust supplier qualification processes will reduce exposure to tariff-driven cost shifts and logistical disruptions. Manufacturers should map critical component dependencies, maintain strategic inventory buffers for key parts, and pursue dual sourcing where feasible. Third, customer-centric commercialization requires tailored training programs, flexible financing models, and outcome-focused service agreements that align incentives between vendors and providers. Emphasizing ease of use, maintenance simplicity, and rapid access to technical support will accelerate device adoption across diverse care settings.

Finally, prioritizing interoperability with imaging systems, electronic health records, and laboratory information systems will create compelling value for integrated care teams. Open APIs, standardized data exports, and secure cloud connectivity can facilitate multidisciplinary workflows and support the growing demand for data-driven diagnostics. By executing on these strategic pillars, organizations can reduce risk, enhance clinical impact, and achieve sustainable growth.

Transparent mixed-methods research methodology integrating primary clinician insights, technical device reviews, regulatory literature, and scenario analysis to support robust conclusions

The research approach combines qualitative expert interviews, device performance reviews, and comparative analysis of regulatory and clinical literature to create a robust and defensible evidence base. Primary inputs included structured discussions with interventional radiologists, thoracic and breast surgeons, pathologists, and procurement professionals to capture real-world procedural preferences, pain points, and adoption drivers. These perspectives were contextualized with technical assessments of device architectures, manufacturing considerations, and service models to align clinical needs with engineering realities.

Secondary research synthesized peer-reviewed clinical studies, regulatory filings, guidelines from professional societies, and supplier technical documents to validate claims related to sample quality, complication rates, and device usability. The methodology emphasized cross-validation between primary insights and published evidence to reduce bias and to ensure that conclusions reflect both practice and documented outcomes. Scenario analysis was used to evaluate supply chain responses to tariff changes and to assess how varying procurement models influence adoption in different institutional settings.

Throughout, the emphasis was on transparent sourcing, reproducible analytic steps, and the inclusion of diverse stakeholder voices to produce actionable findings that resonate with clinicians, procurement leaders, and corporate strategists.

Concise conclusion synthesizing technological progress, clinical validation imperatives, and supply chain considerations that define strategic priorities for biopsy device stakeholders

In sum, biopsy devices are at an inflection point where technological advancements, changing clinical workflows, and external economic pressures converge to create both risk and opportunity. Innovations in targeting accuracy, automation, and platform interoperability are enhancing diagnostic pathways, while provider expectations and payer scrutiny are elevating the need for clear evidence of clinical and operational value. Tariff developments and supply chain responses are accelerating strategic shifts toward localization and resilience, making it imperative for stakeholders to proactively assess risks and adjust procurement and manufacturing strategies.

Organizations that align product development with clinician needs, invest in rigorous outcomes research, and build adaptable supply chains will be best positioned to capture the benefits of this evolving landscape. Collaboration across the ecosystem-including imaging partners, pathology services, and health systems-will further amplify impact and support more personalized and efficient diagnostic pathways. Ultimately, pragmatic execution of evidence-driven innovation and risk mitigation strategies will determine who leads in this dynamic sector.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biopsy Devices Market, by Product Type

  • 8.1. Core Needle
    • 8.1.1. Automatic
    • 8.1.2. Semi Automatic
  • 8.2. Endoscopic
    • 8.2.1. Flexible
    • 8.2.2. Rigid
  • 8.3. Fine Needle Aspiration
    • 8.3.1. Aspiration
    • 8.3.2. Manual
  • 8.4. Vacuum Assisted
    • 8.4.1. Console Based
    • 8.4.2. Handheld

9. Biopsy Devices Market, by Guidance Technique

  • 9.1. Image-Guided Biopsy
  • 9.2. Non-Image-Guided Biopsy

10. Biopsy Devices Market, by Application

  • 10.1. Breast
    • 10.1.1. Diagnostic
    • 10.1.2. Screening
  • 10.2. Kidney
    • 10.2.1. Open
    • 10.2.2. Percutaneous
  • 10.3. Liver
    • 10.3.1. Percutaneous
    • 10.3.2. Transjugular
  • 10.4. Lung
    • 10.4.1. Transbronchial
    • 10.4.2. Transthoracic
  • 10.5. Prostate
    • 10.5.1. Transperineal
    • 10.5.2. Transrectal

11. Biopsy Devices Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Clinics
  • 11.3. Diagnostic Laboratories
  • 11.4. Hospitals

12. Biopsy Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Biopsy Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Biopsy Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Biopsy Devices Market

16. China Biopsy Devices Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Angiotech Pharmaceuticals, Inc.
  • 17.6. Argon Medical Devices, Inc.
  • 17.7. B. Braun Melsungen AG
  • 17.8. Becton, Dickinson and Company
  • 17.9. Boston Scientific Corporation
  • 17.10. Cardinal Health, Inc.
  • 17.11. CONMED Corporation
  • 17.12. Cook Group Incorporated
  • 17.13. Danaher Corporation
  • 17.14. DTR Medical Ltd. by Innovia Medical
  • 17.15. Fujifilm Holdings Corporation
  • 17.16. Gallini Srl
  • 17.17. Hologic, Inc.
  • 17.18. INRAD, Inc.
  • 17.19. Intact Medical Corporation
  • 17.20. Integra LifeSciences Corporation
  • 17.21. Leica Biosystems Nussloch GmbH
  • 17.22. Medtronic PLC
  • 17.23. Merit Medical Systems
  • 17.24. Olympus Corporation
  • 17.25. Precision Biopsy, LLC
  • 17.26. Scion Medical Technologies, LLC
  • 17.27. Stryker Corporation
  • 17.28. TransMed7, LLC
  • 17.29. TSK Laboratory Europe BV

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOPSY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOPSY DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIOPSY DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNIQUE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIOPSY DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOPSY DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIOPSY DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BIOPSY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BIOPSY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIOPSY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOPSY DEVICES MARKET SIZE, BY AUTOMATIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOPSY DEVICES MARKET SIZE, BY AUTOMATIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOPSY DEVICES MARKET SIZE, BY AUTOMATIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOPSY DEVICES MARKET SIZE, BY SEMI AUTOMATIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOPSY DEVICES MARKET SIZE, BY SEMI AUTOMATIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIOPSY DEVICES MARKET SIZE, BY SEMI AUTOMATIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOPSY DEVICES MARKET SIZE, BY FLEXIBLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIOPSY DEVICES MARKET SIZE, BY FLEXIBLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOPSY DEVICES MARKET SIZE, BY FLEXIBLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIOPSY DEVICES MARKET SIZE, BY RIGID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOPSY DEVICES MARKET SIZE, BY RIGID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIOPSY DEVICES MARKET SIZE, BY RIGID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOPSY DEVICES MARKET SIZE, BY ASPIRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIOPSY DEVICES MARKET SIZE, BY ASPIRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOPSY DEVICES MARKET SIZE, BY ASPIRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIOPSY DEVICES MARKET SIZE, BY MANUAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOPSY DEVICES MARKET SIZE, BY MANUAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIOPSY DEVICES MARKET SIZE, BY MANUAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CONSOLE BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CONSOLE BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CONSOLE BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIOPSY DEVICES MARKET SIZE, BY HANDHELD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOPSY DEVICES MARKET SIZE, BY HANDHELD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIOPSY DEVICES MARKET SIZE, BY HANDHELD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIOPSY DEVICES MARKET SIZE, BY IMAGE-GUIDED BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOPSY DEVICES MARKET SIZE, BY IMAGE-GUIDED BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIOPSY DEVICES MARKET SIZE, BY IMAGE-GUIDED BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOPSY DEVICES MARKET SIZE, BY NON-IMAGE-GUIDED BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIOPSY DEVICES MARKET SIZE, BY NON-IMAGE-GUIDED BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOPSY DEVICES MARKET SIZE, BY NON-IMAGE-GUIDED BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOPSY DEVICES MARKET SIZE, BY BREAST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIOPSY DEVICES MARKET SIZE, BY BREAST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOPSY DEVICES MARKET SIZE, BY BREAST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIOPSY DEVICES MARKET SIZE, BY BREAST, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOPSY DEVICES MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIOPSY DEVICES MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOPSY DEVICES MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIOPSY DEVICES MARKET SIZE, BY SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOPSY DEVICES MARKET SIZE, BY SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIOPSY DEVICES MARKET SIZE, BY SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOPSY DEVICES MARKET SIZE, BY KIDNEY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIOPSY DEVICES MARKET SIZE, BY KIDNEY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOPSY DEVICES MARKET SIZE, BY KIDNEY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIOPSY DEVICES MARKET SIZE, BY KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOPSY DEVICES MARKET SIZE, BY OPEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BIOPSY DEVICES MARKET SIZE, BY OPEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOPSY DEVICES MARKET SIZE, BY OPEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PERCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PERCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PERCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOPSY DEVICES MARKET SIZE, BY LIVER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIOPSY DEVICES MARKET SIZE, BY LIVER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOPSY DEVICES MARKET SIZE, BY LIVER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BIOPSY DEVICES MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PERCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PERCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PERCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSJUGULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSJUGULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSJUGULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOPSY DEVICES MARKET SIZE, BY LUNG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BIOPSY DEVICES MARKET SIZE, BY LUNG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOPSY DEVICES MARKET SIZE, BY LUNG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BIOPSY DEVICES MARKET SIZE, BY LUNG, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSBRONCHIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSBRONCHIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSBRONCHIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSTHORACIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSTHORACIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSTHORACIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PROSTATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PROSTATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PROSTATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PROSTATE, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSPERINEAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSPERINEAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSPERINEAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSRECTAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSRECTAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSRECTAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BIOPSY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BIOPSY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BIOPSY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BIOPSY DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BIOPSY DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BIOPSY DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BIOPSY DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL BIOPSY DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BIOPSY DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BIOPSY DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS BIOPSY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS BIOPSY DEVICES MARKET SIZE, BY BREAST, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS BIOPSY DEVICES MARKET SIZE, BY KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS BIOPSY DEVICES MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS BIOPSY DEVICES MARKET SIZE, BY LUNG, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS BIOPSY DEVICES MARKET SIZE, BY PROSTATE, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY BREAST, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY LUNG, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY PROSTATE, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY BREAST, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY LUNG, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY PROSTATE, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY BREAST, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY LUNG, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY PROSTATE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE BIOPSY DEVICES MARKET SIZE, BY BREAST, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE BIOPSY DEVICES MARKET SIZE, BY KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE BIOPSY DEVICES MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE BIOPSY DEVICES MARKET SIZE, BY LUNG, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE BIOPSY DEVICES MARKET SIZE, BY PROSTATE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST BIOPSY DEVICES MARKET SIZE, BY BREAST, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST BIOPSY DEVICES MARKET SIZE, BY KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST BIOPSY DEVICES MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST BIOPSY DEVICES MARKET SIZE, BY LUNG, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST BIOPSY DEVICES MARKET SIZE, BY PROSTATE, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA BIOPSY DEVICES MARKET SIZE, BY BREAST, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA BIOPSY DEVICES MARKET SIZE, BY KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA BIOPSY DEVICES MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA BIOPSY DEVICES MARKET SIZE, BY LUNG, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA BIOPSY DEVICES MARKET SIZE, BY PROSTATE, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC BIOPSY DEVICES MARKET SIZE, BY BREAST, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC BIOPSY DEVICES MARKET SIZE, BY KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC BIOPSY DEVICES MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC BIOPSY DEVICES MARKET SIZE, BY LUNG, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC BIOPSY DEVICES MARKET SIZE, BY PROSTATE, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL BIOPSY DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN BIOPSY DEVICES MARKET SIZE, BY BREAST, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN BIOPSY DEVICES MARKET SIZE, BY KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN BIOPSY DEVICES MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN BIOPSY DEVICES MARKET SIZE, BY LUNG, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN BIOPSY DEVICES MARKET SIZE, BY PROSTATE, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. GCC BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. GCC BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. GCC BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 245. GCC BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 246. GCC BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2032 (USD MILLION)
  • TABLE 247. GCC BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 248. GCC BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 249. GCC BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 250. GCC BIOPSY DEVICES MARKET SIZE, BY BREAST, 2018-2032 (USD MILLION)
  • TABLE 251. GCC BIOPSY DEVICES MARKET SIZE, BY KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 252. GCC BIOPSY DEVICES MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 253. GCC BIOPSY DEVICES MARKET SIZE, BY LUNG, 2018-2032 (USD MILLION)
  • TABLE 254. GCC BIOPSY DEVICES MARKET SIZE, BY PROSTATE, 2018-2032 (USD MILLION)
  • TABLE 255. GCC BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION BIOPSY DEVICES MARKET SIZE, BY BREAST, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION BIOPSY DEVICES MARKET SIZE, BY KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION BIOPSY DEVICES MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION BIOPSY DEVICES MARKET SIZE, BY LUNG, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION BIOPSY DEVICES MARKET SIZE, BY PROSTATE, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS BIOPSY DEVICES MARKET SIZE, BY BREAST, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS BIOPSY DEVICES MARKET SIZE, BY KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS BIOPSY DEVICES MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS BIOPSY DEVICES MARKET SIZE, BY LUNG, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS BIOPSY DEVICES MARKET SIZE, BY PROSTATE, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 284. G7 BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 285. G7 BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. G7 BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 287. G7 BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 288. G7 BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2032 (USD MILLION)
  • TABLE 289. G7 BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 290. G7 BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 291. G7 BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 292. G7 BIOPSY DEVICES MARKET SIZE, BY BREAST, 2018-2032 (USD MILLION)
  • TABLE 293. G7 BIOPSY DEVICES MARKET SIZE, BY KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 294. G7 BIOPSY DEVICES MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 295. G7 BIOPSY DEVICES MARKET SIZE, BY LUNG, 2018-2032 (USD MILLION)
  • TABLE 296. G7 BIOPSY DEVICES MARKET SIZE, BY PROSTATE, 2018-2032 (USD MILLION)
  • TABLE 297. G7 BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 298. NATO BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 299. NATO BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. NATO BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 301. NATO BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 302. NATO BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2032 (USD MILLION)
  • TABLE 303. NATO BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 304. NATO BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 305. NATO BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 306. NATO BIOPSY DEVICES MARKET SIZE, BY BREAST, 2018-2032 (USD MILLION)
  • TABLE 307. NATO BIOPSY DEVICES MARKET SIZE, BY KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 308. NATO BIOPSY DEVICES MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 309. NATO BIOPSY DEVICES MARKET SIZE, BY LUNG, 2018-2032 (USD MILLION)
  • TABLE 310. NATO BIOPSY DEVICES MARKET SIZE, BY PROSTATE, 2018-2032 (USD MILLION)
  • TABLE 311. NATO BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 312. GLOBAL BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED STATES BIOPSY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED STATES BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED STATES BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED STATES BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED STATES BIOPSY DEVICES MARKET SIZE, BY BREAST, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED STATES BIOPSY DEVICES MARKET SIZE, BY KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED STATES BIOPSY DEVICES MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED STATES BIOPSY DEVICES MARKET SIZE, BY LUNG, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED STATES BIOPSY DEVICES MARKET SIZE, BY PROSTATE, 2018-2032 (USD MILLION)
  • TABLE 326. UNITED STATES BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 327. CHINA BIOPSY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 328. CHINA BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 329. CHINA BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 330. CHINA BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 331. CHINA BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2032 (USD MILLION)
  • TABLE 332. CHINA BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 333. CHINA BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 334. CHINA BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 335. CHINA BIOPSY DEVICES MARKET SIZE, BY BREAST, 2018-2032 (USD MILLION)
  • TABLE 336. CHINA BIOPSY DEVICES MARKET SIZE, BY KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 337. CHINA BIOPSY DEVICES MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 338. CHINA BIOPSY DEVICES MARKET SIZE, BY LUNG, 2018-2032 (USD MILLION)
  • TABLE 339. CHINA BIOPSY DEVICES MARKET SIZE, BY PROSTATE, 2018-2032 (USD MILLION)
  • TABLE 340. CHINA BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)